New hope for Alzheimer's psychosis: 52-Week safety trial launches
NCT ID NCT07459660
First seen Apr 07, 2026 · Last updated May 19, 2026 · Updated 9 times
Summary
This study looks at the long-term safety of an experimental drug called ML007C-MA for people with Alzheimer's disease who experience hallucinations and delusions. It is a 52-week open-label extension for 210 adults who completed a prior study. The goal is to see if the drug remains safe and tolerable over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site
RECRUITINGDoral, Florida, 33122, United States
-
Clinical Site
RECRUITINGMiami, Florida, 33155, United States
-
Clinical Site
RECRUITINGMiami, Florida, 33173, United States
Conditions
Explore the condition pages connected to this study.